Search Results

Title: A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2) MOA: IINCA033989 inhibits mutCALR induced JAK/STAT signaling and oncogenic cell proliferation. Key Eligibility Confirmed diagnosis of high-risk ET Presence of a pathogenic CALR exon 9 mutationbased on…

Title: A Phase 2/3, randomized, open-label, active-comparator-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of bomedemstat(MK-3543) versus best available therapy in participants with polycythemia vera who have an inadequate response to or are intolerant to hydroxyurea (MK-3543-025) MOA: Bomedemstat (MK-3543) is an irreversible inhibitor of LSD1. Key Eligibility: Subjects must have a confirmed…

Breast cancer treatment has evolved dramatically over the past decade, offering patients more personalized and effective options than ever before. While surgery, chemotherapy, radiation therapy, and hormone therapy remain important components of care, new advancements in immunotherapy, targeted therapies, and antibody-drug conjugates (ADCs) are transforming outcomes and providing hope for patients facing even the most…

While anyone can develop pancreatic cancer, researchers have identified several factors that may increase the risk of the disease. Understanding these risk factors does not mean you will develop pancreatic cancer. Many people with known risk factors never receive a diagnosis, while others with no identifiable risks do. However, awareness can help you make informed…

Parker Fulghum is a certified Physician Assistant dedicated to providing compassionate, patient-centered, and evidence-based care. She received her bachelor’s degree in biology from The College of William & Mary and then went on to earn her master’s degree from the George Washington University Physician Assistant Program. During her time at GW, she developed a strong…

A breast cancer diagnosis can raise many questions about treatment, prognosis, and whether the disease may be hereditary. Genetic testing has become an important tool in helping patients and their families better understand inherited cancer risks, make informed healthcare decisions, and identify opportunities for personalized treatment. Today, advances in genetic testing are providing valuable insights…